It does matter, and it matters a lot. Retail investors have a limited tolerance for pain and numbers that you are talking would kill this company. It would make this company soo cheap that we would then have to worry about a takeover. You guys that constantly say it doesn't matter because I'm here for the long haul had better understand that it matters to the company and the rest of the investors. We don't want an identity that the stock is a non performer even with game changing tech and a cure for cancer. Although, it doesn't seem to matter to Dr. Kim either. This science, this platform is an easy buyout the lower the pps goes. It matters to me.
Yes, we have a very talented Scientist leading the company, and yes, we have a complete amateur running the finance side of the company. All this shorting is the result of all the dilution and doubt cast by the RS which held investors back until the results of P2. couldn't ask for a better scenario than that. Set this stock up for this manipulation and it won't be over anytime soon. He opened the doors to heii when he decided to dump all the retail faithful in favor of the folks waving fists full of $20 bills in front of his eyes. He will never admit it, but I have seen it over and over on smaller scales many times. A very expensive short cut to the big leagues for the retail faithful.
Well, that's your opinion. I seem to be able to buy shares every day cheaper and cheaper. They are coming from somewhere.
NOthing wrong with AF and his ilk taking advantage of management mistakes, it happens every day. It is up to the company to provide PR and assurances to shareholders otherwise we are left to fend for ourselves without benefit of the media. We just experienced the biggest and most anticipated event in the company's history and the result in pps is atrocious due to dilution of shareholders. We not only proved that we are curing cancer, but validated our platform and our pipeline and now have to fight off the shorts who are stronger than ever.
I am convinced that were we at $3 or so going into P2 without the RS wrapped around our necks we would of easily passed $5 on the results and that the buying on that news would of moved us higher still. An RS following the results would of put us over $20. The RS as it was done cast doubt on P2 results and gave investors reason to wait the results and then beat the pps back down so they can buy at a great entry point knowing where the science is going. At this point I consider Dr. Kim's decisions to be poorly timed at best. Only time will tell weather or not he is right in handling of the financials at this crucial time in development.
The correct move was to sell on the RS news (I only sold a third) my bad, and buy back after the RS, sell the P2 results and buy back as it is driven back down. I held lots of cash and buy some every day as I don't know when the big's will be satisfied. I feel Dr. Kim is in a hurry to make this company a big player and it will provide many buying ops for those patient enough to suck up those retail shares.
Well, they have to make the best of the data, but it is what it is and it shouldn't take too much time. Numbers speak for themselves I think, so there isn't a whole lot of understanding that has to go into it. Perhaps I'm wrong, but.......I'll have to give them the benefit of the doubt. Unfortunately, it will be very expensive the longer they take and you don't have to be a genius to understand that.